📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,076
All-time analysed
43,619
Positive
6,746
Negative
92,864
Neutral
8,779
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
848 announcements match the current filters (relevance ≥ 5).
Concord Biotech Recommends ₹7.55 Dividend and Approves FY26 Financial Results
Concord Biotech's Board has recommended a final dividend of ₹7.55 per equity share for the financial year ended March 31, 2026. The company reported audited financial results for both standalone and consolidated entities with an unmodified audit opinion from BSR & Co. LLP. To strengthen governance, the board appointed Mrs. Ekta Gupta as an Additional Independent Director for a five-year term. The record date for the dividend payout is set for July 24, 2026, subject to shareholder approval.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.
Fixed July 24, 2026, as the record date for identifying shareholders eligible for the dividend payout.
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term starting June 1, 2026.
Statutory auditors issued an unmodified opinion on the standalone and consolidated financial results for FY26.
Appointed Manubhai & Shah LLP and Dalwadi & Associates as Internal and Cost Auditors respectively for FY27.
👀 What to Watch
Investors should ensure they hold the shares by the record date of July 24, 2026, to qualify for the ₹7.55 dividend. The clean audit report and addition of an independent director reflect stable corporate governance.
Tasty Bite FY26 PAT Jumps 38% to ₹353M; Company Becomes Debt-Free with ₹10 Dividend
Tasty Bite Eatables reported a flat revenue of ₹5,716 million for FY26, but achieved a significant 38% growth in Profit After Tax (PAT) to ₹353 million. The company successfully transitioned to a debt-free status after repaying all borrowings and proposed a 100% dividend of ₹10 per share, which is five times higher than the previous year. While the US affiliate business declined by 40% due to macroeconomic headwinds, the Mars Affiliate business surged by 148% and the Food Service segment grew by 18%. Operational efficiencies led to a 250 bps expansion in EBITDA margins to 14.8%, despite increased spending on brand building.
Key Highlights
FY26 Profit After Tax (PAT) increased by 38% YoY to ₹353 million, driven by higher EBITDA and lower interest costs.
EBITDA margins expanded by 250 bps to 14.8% through operational efficiencies and strict control on fixed costs.
The company is now fully debt-free after repaying all borrowings and has proposed a dividend of ₹10 per share.
Food Service business recorded its 10th consecutive quarter of growth, rising 18% in FY26.
Mars Affiliate business grew 148% YoY, helping offset a 40% decline in the PBI US Affiliate segment caused by US tariff challenges.
👀 What to Watch
Investors should take confidence in the company's debt-free status and significant margin expansion despite flat top-line growth. The strategic pivot toward domestic food services and quick-commerce platforms like Zepto offers a promising hedge against volatile US export revenues.
Tasty Bite Declares Rs 10 Dividend; Auditor Issues Qualified Opinion Over Related Party Transactions
Tasty Bite Eatables has recommended a final dividend of Rs 10 per share for FY26, despite reporting a qualified audit opinion. The company reported a total income of INR 5,716.22 million and a net profit of INR 353.02 million for the fiscal year. However, a major governance concern has emerged as shareholders rejected post-facto approval for material related party transactions exceeding thresholds by INR 94.47 million. The auditor has expressed inability to determine the consequential effects of this shareholder dissent on the financial statements.
Key Highlights
Recommended a final dividend of Rs 10 per equity share for the financial year ended March 31, 2026.
Reported annual total income of INR 5,716.22 million and net profit of INR 353.02 million.
Auditors issued a qualified opinion regarding unauthorized related party transactions totaling approximately INR 143.39 million.
Shareholders officially dissented and rejected the postal ballot for post-facto approval of material related party transactions.
Earnings Per Share (EPS) for the full year was reported at INR 137.57.
👀 What to Watch
While the dividend is a positive yield event, the shareholder rejection of related party transactions and the qualified audit opinion are significant governance red flags. Investors should wait for management's clarification on how they intend to resolve the unauthorized transactions before making new commitments.
Tasty Bite FY26 Net Profit at ₹353M; Auditor Issues Qualified Opinion on Related Party Transactions
Tasty Bite Eatables reported a total income of ₹5,716.22 million and a net profit of ₹353.02 million for the fiscal year ended March 31, 2026. While the company recommended a final dividend of ₹10 per share, the statutory auditors issued a qualified opinion regarding governance lapses. Specifically, the company failed to obtain prior approvals for related party transactions (RPT) totaling approximately ₹143 million. Most concerningly, shareholders have already voted against and rejected the post-facto approval for these material transactions, creating regulatory uncertainty.
Key Highlights
Reported FY26 total income of ₹5,716.22 million and net profit of ₹353.02 million.
Recommended a final dividend of ₹10 per equity share for the financial year.
Auditors flagged ₹48.92 million in RPTs conducted without prior Audit Committee approval.
Material RPTs exceeded regulatory thresholds by ₹94.47 million without required prior shareholder approval.
Shareholders officially dissented and rejected the post-facto approval for the material RPTs via postal ballot.
👀 What to Watch
Investors should exercise caution as the audit qualification and shareholder rejection of management's RPTs signal significant governance risks. Monitor for potential regulatory penalties or legal actions arising from the unauthorized transactions.
Gufic Biosciences Q4 Net Profit Surges 184% YoY to ₹21.9 Cr; FY26 Revenue Up 15%
Gufic Biosciences reported a robust Q4 FY26 performance with consolidated revenue growing 22.8% YoY to ₹251.8 crore and net profit jumping 183.6% to ₹21.9 crore. For the full financial year 2025-26, revenue increased by 15.1% to ₹944 crore, although annual net profit saw a slight decline of 7.8% to ₹64.2 crore due to increased finance and depreciation costs. The company has recommended a final dividend of ₹0.10 per share. A significant increase in inventory and short-term borrowings was observed, which impacted the operating cash flow for the year.
Key Highlights
Q4 FY26 consolidated revenue rose 22.8% YoY to ₹251.82 crore from ₹205.02 crore.
Q4 FY26 net profit surged 183.6% YoY to ₹21.90 crore compared to ₹7.72 crore in the previous year's quarter.
Full-year FY26 revenue reached ₹944.01 crore, up from ₹819.81 crore in FY25.
Recommended a final dividend of ₹0.10 per equity share (10% of face value).
Short-term borrowings increased significantly to ₹280.13 crore from ₹179.88 crore YoY.
👀 What to Watch
The strong Q4 recovery indicates a positive turnaround in operational performance; however, investors should monitor the rising debt levels and inventory buildup which have pressured cash flows. The stock remains a 'Watch' to see if the Q4 margin expansion is sustainable into the next fiscal year.
Gufic Bio Q4 Net Profit Surges 183% YoY to ₹21.9 Cr; FY26 Revenue Up 15%
Gufic Biosciences reported a robust Q4 FY26 with consolidated revenue growing 22.8% YoY to ₹251.8 crore. Net profit for the quarter saw a massive jump of 183% YoY, reaching ₹21.9 crore compared to ₹7.7 crore in the previous year's quarter. However, on a full-year basis, while revenue grew 15.1% to ₹944 crore, net profit declined by 7.8% to ₹64.2 crore due to higher finance costs and depreciation. The board has recommended a final dividend of ₹0.10 per equity share for FY26.
Key Highlights
Q4 FY26 Consolidated Revenue increased 22.8% YoY to ₹251.8 crore.
Q4 FY26 Consolidated Net Profit surged 183% YoY to ₹21.9 crore.
Full-year FY26 Revenue grew 15.1% to ₹944 crore, while Net Profit fell 7.8% to ₹64.2 crore.
Finance costs for the full year increased significantly to ₹36.6 crore from ₹23.1 crore.
Inventory levels rose sharply to ₹324.5 crore from ₹216.9 crore YoY.
👀 What to Watch
Investors should cheer the strong Q4 recovery but remain cautious about the full-year profit dip and rising debt levels. Monitor the company's ability to manage working capital as inventory and borrowings have increased significantly.
BIL Vyapar Reports FY26 Results Under CIRP; Auditors Issue Disclaimer of Opinion
BIL Vyapar Limited (formerly Binani Industries) has released its FY26 financial results while undergoing Corporate Insolvency Resolution Process (CIRP). The statutory auditors have issued a Disclaimer of Opinion, stating they could not obtain sufficient evidence to provide a basis for an audit opinion. The company's net worth is completely eroded with accumulated losses of INR 21,766.17 lakhs, and current liabilities exceed current assets by INR 18,627.68 lakhs. Consequently, the financial statements have been prepared on a liquidation basis rather than as a going concern.
Key Highlights
Auditors issued a Disclaimer of Opinion for FY26 due to lack of evidence on asset valuations and liabilities.
Accumulated losses reached INR 21,766.17 lakhs, resulting in total erosion of net worth.
Current liabilities exceed current assets by INR 18,627.68 lakhs as of March 31, 2026.
Financials are prepared on a liquidation basis as the 'going concern' assumption is no longer valid.
Outstanding corporate guarantees of INR 8,025 lakhs for Edayar Zinc Limited remain a significant admitted claim.
👀 What to Watch
Investors should exercise extreme caution as the company is in insolvency proceedings and the auditors cannot verify the financial statements. The preparation of accounts on a liquidation basis indicates a high risk that equity shareholders may receive little to no value during the resolution process.
BIL Vyapar Reports FY26 Results Under CIRP; Auditors Issue Disclaimer of Opinion
BIL Vyapar Limited (formerly Binani Industries) reported its FY26 results under the Corporate Insolvency Resolution Process (CIRP), with the Committee of Creditors approving the financials. The auditors have issued a 'Disclaimer of Opinion,' stating they cannot verify asset valuations, corporate guarantees of ₹80.25 crore, or the status of various land parcels. The company's net worth is completely eroded with accumulated losses of ₹217.66 crore, and the accounts have been prepared on a liquidation basis. Significant uncertainties remain regarding the recoverability of ₹11.46 crore in tax receivables and the impact of ongoing legal disputes.
Key Highlights
Auditors issued a Disclaimer of Opinion for FY26 due to lack of sufficient audit evidence on key financial matters.
Accumulated losses reached ₹217.66 crore, with current liabilities exceeding current assets by ₹186.28 crore.
Financial statements are prepared on a 'Liquidation Basis' as the going concern assumption is no longer valid.
Outstanding corporate guarantees of ₹80.25 crore for Edayar Zinc Limited remain admitted claims in the CIRP.
Discrepancies found in land records, including Sirohi land still on books despite being sold in earlier years.
👀 What to Watch
Investors should exercise extreme caution as the company is in insolvency and the auditor's disclaimer suggests financial records may not be reliable. Equity value is at high risk of being completely wiped out during the resolution or liquidation process.
BIL Vyapar Reports Full Net Worth Erosion; Auditors Issue Disclaimer on FY26 Results
BIL Vyapar Limited (formerly Binani Industries) is currently under the Corporate Insolvency Resolution Process (CIRP), with its Board of Directors suspended. The company reported accumulated losses of ₹21,766.17 lakhs as of March 31, 2026, resulting in a total erosion of net worth. Statutory auditors have issued a 'Disclaimer of Opinion' due to significant uncertainties, including lack of access to asset valuation reports and discrepancies in land records. Consequently, the financial statements have been prepared on a liquidation basis rather than as a going concern.
Key Highlights
Accumulated losses reached ₹21,766.17 lakhs, with current liabilities exceeding current assets by ₹18,627.68 lakhs.
Statutory auditors issued a 'Disclaimer of Opinion' for FY26, citing inability to obtain sufficient appropriate audit evidence.
Financial results are prepared on a 'liquidation basis' as the going concern assumption is no longer appropriate.
Lenders have admitted claims of ₹8,025 lakhs related to corporate guarantees for Edayar Zinc Limited.
Discrepancies found in asset records, including a property in Ahmedabad sold at a loss of ₹33.51 lakhs that was not accounted for in the books.
👀 What to Watch
Investors should exercise extreme caution as the company is in insolvency proceedings and its net worth is completely eroded. In such liquidation scenarios, equity shareholders typically stand last in the priority of claims and may face a total loss of capital.
Biocon Revises Preferential Issue Price to ₹376.41 and Sets Swap Ratio for Biologics Unit
Biocon Limited has issued a corrigendum to its May 07, 2026, Postal Ballot Notice regarding a preferential issue of equity shares for non-cash consideration. The company will issue 8,786,362 shares to acquire stakes from Biocon Biologics Limited (BBL) shareholders. Following stock exchange feedback, the floor price is now ₹373.08, with an issue price of ₹376.41 per share. The revised swap ratio is approximately 76.16 Biocon Ltd shares for every 100 BBL shares held by the selling shareholders.
Key Highlights
Issuance of 87,86,362 equity shares on a preferential basis for consideration other than cash
Revised issue price fixed at ₹376.41 per share based on updated valuation methodology
Swap ratio set at 0.76159 Biocon Ltd shares for every 100 Biocon Biologics Limited shares
Floor price determined at ₹373.08 based on 90-day volume weighted average price (VWAP)
The transaction consolidates ownership in the Biologics subsidiary by acquiring shares from various individual stakeholders
👀 What to Watch
Investors should monitor the impact of the 8.78 million share dilution against the long-term benefit of consolidating the Biologics business. No immediate action is required as this is a technical adjustment to a previously announced corporate action.
SBI Life Appoints Ramesh Venkateshamurthy as Deputy CEO Effective May 29, 2026
SBI Life Insurance has appointed Mr. Ramesh Venkateshamurthy as the new Deputy Chief Executive Officer, effective May 29, 2026. Mr. Venkateshamurthy transitions from State Bank of India (SBI), where he most recently served as General Manager (Yono Retail) & UPI since June 2023. His extensive background in digital banking and customer experience at SBI is expected to bolster SBI Life's digital transformation initiatives. The appointment follows a recommendation by the Board Nomination and Remuneration Committee.
Key Highlights
Mr. Ramesh Venkateshamurthy appointed as Deputy CEO effective May 29, 2026.
Served as General Manager (Yono Retail) & UPI at SBI, managing the bank's UPI portfolio since June 2023.
Previously held the position of Deputy General Manager - Customer Experience at SBI's Corporate Centre.
Brings significant experience in digital marketing and propagating digital banking products through various channels.
👀 What to Watch
Investors should monitor how the new Deputy CEO's digital expertise influences SBI Life's direct-to-customer digital sales and operational efficiency. No immediate portfolio changes are recommended based on this leadership update.
Concord Biotech Recommends ₹7.55 Dividend; Appoints New Independent Director
Concord Biotech's board has recommended a final dividend of ₹7.55 per share for FY 2025-26, subject to shareholder approval. The company reported audited financial results for the year ended March 31, 2026, receiving a clean, unmodified opinion from its statutory auditors. In a move to strengthen governance, Mrs. Ekta Gupta has been appointed as an Additional Independent Director for a five-year term. The board also finalized the appointment of new internal and cost auditors for the 2026-27 fiscal year.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 each for FY 2025-26
Fixed July 24, 2026, as the record date for identifying eligible shareholders for dividend payment
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term starting June 1, 2026
Statutory auditors BSR & Co. LLP issued an unmodified audit opinion for the FY26 financial results
Appointed M/s. Manubhai & Shah LLP as Internal Auditor for the financial year 2026-27
👀 What to Watch
Investors should ensure they hold the stock before the July 24, 2026, record date to be eligible for the ₹7.55 dividend. The clean audit report and board expansion are positive indicators of corporate governance and stability.
Concord Biotech Approves FY26 Results, Recommends ₹7.55 Dividend, Appoints New Director
Concord Biotech has approved its audited financial results for the fiscal year ended March 31, 2026, with an unmodified audit opinion. The Board recommended a dividend of ₹7.55 per equity share (755% of face value), setting July 24, 2026, as the record date. Additionally, Mrs. Ekta Gupta has been appointed as an Independent Director for a five-year term starting June 1, 2026. The company also finalized the appointment of internal and cost auditors for the 2026-27 fiscal year.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.
Appointed Mrs. Ekta Gupta as Additional Independent Director for a 5-year term effective June 1, 2026.
Approved audited standalone and consolidated financial results for FY26 with an unmodified audit opinion.
Fixed July 24, 2026, as the record date for dividend eligibility.
Appointed M/s. Manubhai & Shah LLP as Internal Auditor and M/s. Dalwadi & Associates as Cost Auditor for FY 2026-27.
👀 What to Watch
Investors should track the record date of July 24, 2026, to be eligible for the ₹7.55 dividend payout. The unmodified audit report and the addition of a seasoned professional to the board reflect strong governance and financial stability.
Concord Biotech Recommends ₹7.55 Final Dividend; Sets Record Date for July 2026
Concord Biotech Limited has recommended a final dividend of ₹7.55 per equity share for the financial year 2025-26. The board has fixed July 24, 2026, as the record date to determine shareholder eligibility for the payout, pending approval at the upcoming Annual General Meeting. In addition to the dividend, the company reported audited financial results for FY26 with an unmodified audit opinion from BSR & Co. LLP. The board also strengthened its governance by appointing Mrs. Ekta Gupta as an Additional Independent Director for a five-year term.
Key Highlights
Recommended a final dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26
Fixed July 24, 2026, as the record date for identifying eligible shareholders for the dividend
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term effective June 1, 2026
Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results for FY26
Approved the appointment of Manubhai & Shah LLP as Internal Auditors and Dalwadi & Associates as Cost Auditors for FY 2026-27
👀 What to Watch
Investors seeking dividend income should ensure they hold shares before the July 24, 2026 record date. The unmodified audit report and board expansion reflect positive corporate governance and financial stability.
Concord Biotech Recommends ₹7.55 Dividend and Approves FY26 Audited Financial Results
Concord Biotech Limited has recommended a final dividend of ₹7.55 per equity share (face value ₹1) for the financial year 2025-26, subject to shareholder approval. The Board approved the audited standalone and consolidated financial results for the year ended March 31, 2026, with statutory auditors issuing an unmodified opinion. Additionally, the company strengthened its board by appointing Mrs. Ekta Gupta as an Additional Independent Director for a five-year term. The record date for the dividend payment has been fixed as July 24, 2026.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.
Fixed July 24, 2026, as the record date for identifying eligible shareholders for dividend payment.
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term effective June 1, 2026.
Statutory auditors BSR & Co. LLP issued an unmodified audit report for both standalone and consolidated results.
Appointed M/s. Manubhai & Shah LLP and M/s. Dalwadi & Associates as Internal and Cost Auditors respectively for FY 2026-27.
👀 What to Watch
Investors should monitor the upcoming AGM for dividend approval and ensure holdings are in place by the July 24, 2026 record date to qualify for the ₹7.55 per share payout.
Rubicon Research Recommends Final Dividend of ₹1.50 per Share for FY26
Rubicon Research Limited's Board of Directors has recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026. This dividend is calculated on a face value of ₹1 per share, representing a 150% payout ratio relative to the face value. The announcement was made alongside the approval of the company's audited financial results for the quarter and full year. The final payout is subject to shareholder approval at the upcoming Annual General Meeting and will be distributed within 30 days of declaration.
Key Highlights
Recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026
Dividend is based on a face value of ₹1.00 per share, reflecting a 150% dividend rate
Audited financial results for Q4 and FY26 approved with an unmodified opinion from Deloitte Haskins & Sells LLP
Dividend payment to be completed within 30 days from the date of declaration at the Annual General Meeting
👀 What to Watch
Investors should monitor for the announcement of the record date to ensure eligibility for the ₹1.50 per share dividend. The unmodified audit report provides additional assurance regarding the company's financial disclosures.
Rubicon Research Recommends ₹1.50 Dividend and Approves ESOP Scheme 2026
Rubicon Research Limited has approved its audited financial results for the quarter and year ended March 31, 2026, with an unmodified auditor's opinion. The Board has recommended a final dividend of ₹1.50 per equity share (150% of face value), pending shareholder approval at the upcoming AGM. Additionally, the company is moving forward with the 'Employees Stock Option Scheme 2026' to incentivize and retain talent across its global operations.
Key Highlights
Recommended a dividend of ₹1.50 per equity share of face value ₹1 for FY 2025-26.
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Statutory auditors Deloitte Haskins & Sells LLP issued a clean, unmodified opinion on the financial statements.
Formulated and adopted the 'Rubicon Research Limited - Employees Stock Option Scheme 2026'.
Consolidated results include performance from 13 global subsidiaries across the US, Canada, Singapore, and Europe.
👀 What to Watch
Investors should monitor the upcoming Annual General Meeting for dividend declaration and review the full financial statement for year-on-year growth metrics. The introduction of the ESOP scheme is a positive indicator of management's focus on long-term human capital stability.
Rubicon Research Q4 PAT Surges 112% to ₹76.8 Cr; Revenue Up 43.5% YoY
Rubicon Research reported robust Q4 FY26 results with revenue growing 43.5% YoY to ₹513.9 crore and PAT doubling to ₹76.8 crore. The company maintained strong EBITDA margins of 23.6% despite increased reliance on outsourced manufacturing due to capacity constraints. Significant progress was made in debt reduction using IPO proceeds, and the acquisition of Arinna Lifesciences marks a strategic entry into the Indian CNS market. With 24 products under USFDA review and 12 approvals received in FY26, the growth trajectory remains strong.
Key Highlights
Q4 FY26 Revenue grew 43.5% YoY to ₹5,139 million; PAT surged 111.8% to ₹768 million.
Full-year FY26 Revenue reached ₹17,540 million with an 83.6% growth in PAT to ₹2,467 million.
Board recommended a 150% dividend (₹1.50 per share) for the financial year.
Utilized IPO proceeds to repay ₹265 crore of debt, improving the debt-to-equity profile.
Acquired 85% stake in Arinna Lifesciences for ₹176 crore to establish a domestic CNS market presence.
👀 What to Watch
The company shows high R&D productivity (5.9x revenue multiple) and a strong product pipeline, making it a compelling growth story. Investors should monitor the Pithampur facility's USFDA inspection as its ramp-up in Q1 CY27 is expected to be margin accretive.
Rubicon Research Recommends INR 1.50 Dividend and Approves Audited FY26 Financial Results
Rubicon Research Limited has approved its audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026. The Board of Directors recommended a final dividend of INR 1.50 per equity share (150% of face value), pending shareholder approval at the upcoming AGM. Statutory auditors Deloitte Haskins & Sells LLP have issued an unmodified opinion on the financial statements, indicating a clean audit. The consolidated results incorporate performance from various global subsidiaries across North America, Europe, and Asia-Pacific.
Key Highlights
Recommended a dividend of INR 1.50 per equity share of face value INR 1/- for the financial year ended March 31, 2026.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Statutory auditors issued an unmodified opinion, confirming the reliability of the financial disclosures.
Dividend payment is scheduled to be completed within 30 days of declaration by members at the AGM.
Consolidated entities include major subsidiaries such as AdvaGen Pharma Limited and Validus Pharmaceutical LLC.
👀 What to Watch
Investors should monitor the detailed financial performance metrics once the full statement is available to assess year-on-year growth. The dividend recommendation offers a steady yield, but the focus should remain on the operational performance of its international pharmaceutical subsidiaries.
Bhartiya International FY26 Net Profit Jumps 59% to ₹33.7 Cr; Revenue Crosses ₹1,130 Cr
Bhartiya International Limited (BIL) reported a strong financial performance for the fiscal year ended March 31, 2026, with annual revenue growing 32% to ₹1,130.54 crore. Net profit for the full year surged by 59.4% to ₹33.71 crore, up from ₹21.15 crore in the previous year. While annual growth was robust, Q4 standalone net profit remained relatively flat at ₹1.51 crore despite a 20% increase in quarterly revenue. The company also announced the re-appointment of Mr. Sanjay Jawa as the Internal Auditor for FY 2026-27.
Key Highlights
Annual Revenue from Operations increased by 32% YoY to ₹1,130.54 crore in FY26.
Net Profit for the full year grew significantly by 59.4% to reach ₹33.71 crore.
Earnings Per Share (EPS) for the year improved to ₹25.48 from ₹17.29 in FY25.
Q4 FY26 revenue stood at ₹244.62 crore, a 20.7% increase over Q4 FY25.
Board approved the re-appointment of Mr. Sanjay Jawa as Internal Auditor for the 2026-27 fiscal year.
👀 What to Watch
Investors should take note of the strong annual top-line and bottom-line growth, though the stagnation in Q4 profits due to rising expenses requires monitoring. The significant jump in annual EPS makes the stock attractive for long-term holders.
